Search Results - "Harshman, Lauren"

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study by Heng, Daniel YC, Dr, Xie, Wanling, MS, Regan, Meredith M, ScD, Harshman, Lauren C, MD, Bjarnason, Georg A, MD, Vaishampayan, Ulka N, MD, Mackenzie, Mary, MD, Wood, Lori, MD, Donskov, Frede, MD, Tan, Min-Han, MD, Rha, Sun-Young, MD, Agarwal, Neeraj, MD, Kollmannsberger, Christian, MD, Rini, Brian I, Prof, Choueiri, Toni K, MD

“…Summary Background The International Metastatic Renal-Cell Carcinoma Database Consortium model offers prognostic information for patients with metastatic…”
Get full text

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) by Francini, Edoardo, Gray, Kathryn P., Xie, Wanling, Shaw, Grace K., Valença, Loana, Bernard, Brandon, Albiges, Laurence, Harshman, Lauren C., Kantoff, Philip W., Taplin, Mary‐Ellen, Sweeney, Cristopher J.

“…Background Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)…”
Get full text

Mind the gap: What is driving the survival disparity between the sexes in bladder cancer? by Harshman, Lauren C.

“…Bladder cancer is well known to preferentially afflict men. However, women are significantly more likely to die of the disease even when corrected for stage,…”
Get full text

Too Much or Just Enough of a Good Thing: Vascular Endothelial Growth Factor Inhibition in Renal Cell Carcinoma? by Harshman, Lauren C

Get full text

Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE) by McKay, Rana R, McGregor, Bradley A, Xie, Wanling, Braun, David A, Wei, Xiao, Kyriakopoulos, Christos E, Zakharia, Yousef, Maughan, Benjamin L, Rose, Tracy L, Stadler, Walter M, McDermott, David F, Harshman, Lauren C, Choueiri, Toni K

“…In this phase II response-adaptive trial, we investigated the rational application of immune checkpoint blockade in renal cell carcinoma (RCC;…”
Get full text

Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder by Seisen, Thomas, Sun, Maxine, Lipsitz, Stuart R, Abdollah, Firas, Leow, Jeffrey J, Menon, Mani, Preston, Mark A, Harshman, Lauren C, Kibel, Adam S, Nguyen, Paul L, Bellmunt, Joaquim, Choueiri, Toni K, Trinh, Quoc-Dien

“…Abstract Given the lack of randomized evidence comparing trimodal therapy (TMT) to radical cystectomy (RC) for muscle-invasive urothelial carcinoma of the…”
Get full text

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis by Sun, Maxine, Marconi, Lorenzo, Eisen, Tim, Escudier, Bernard, Giles, Rachel H., Haas, Naomi B., Harshman, Lauren C., Quinn, David I., Larkin, James, Pal, Sumanta K., Powles, Thomas, Ryan, Christopher W., Sternberg, Cora N., Uzzo, Robert, Choueiri, Toni K., Bex, Axel

“…Contradictory data exist with regard to adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy in surgically managed patients for…”
Get full text

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer by Galsky, Matthew D., Pal, Sumanta K., Chowdhury, Simon, Harshman, Lauren C., Crabb, Simon J., Wong, Yu‐Ning, Yu, Evan Y., Powles, Thomas, Moshier, Erin L., Ladoire, Sylvain, Hussain, Syed A., Agarwal, Neeraj, Vaishampayan, Ulka N., Recine, Federica, Berthold, Dominik, Necchi, Andrea, Theodore, Christine, Milowsky, Matthew I., Bellmunt, Joaquim, Rosenberg, Jonathan E.

“…BACKGROUND Gemcitabine plus cisplatin (GC) has been adopted as a neoadjuvant regimen for muscle‐invasive bladder cancer despite the lack of Level I evidence in…”
Get full text

The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients by Hall, Philip S., MD, Harshman, Lauren C., MD, Srinivas, Sandy, MD, Witteles, Ronald M., MD

“…Objectives The purpose of this study was to document the incidence and extent of cardiovascular toxicity among advanced renal cell carcinoma patients treated…”
Get full text

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features by McGregor, Bradley A, McKay, Rana R, Braun, David A, Werner, Lillian, Gray, Kathryn, Flaifel, Abdallah, Signoretti, Sabina, Hirsch, Michelle S, Steinharter, John A, Bakouny, Ziad, Flippot, Ronan, Wei, Xiao X, Choudhury, Atish, Kilbridge, Kerry, Freeman, Gordon J, Van Allen, Eliezer M, Harshman, Lauren C, McDermott, David F, Vaishampayan, Ulka, Choueiri, Toni K

“…In this multicenter phase II trial, we evaluated atezolizumab combined with bevacizumab in patients with advanced renal cell carcinoma (RCC) with variant…”
Get full text

Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites by Nassar, Amin H, Umeton, Renato, Kim, Jaegil, Lundgren, Kevin, Harshman, Lauren, Van Allen, Eliezer M, Preston, Mark, Dong, Fei, Bellmunt, Joaquim, Mouw, Kent W, Choueiri, Toni K, Sonpavde, Guru, Kwiatkowski, David J

“…The purpose of this study is to characterize the mutational landscape across the spectrum of urothelial carcinoma (UC) to identify mutational features and…”
Get full text

Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma by McGregor, Bradley A., Lalani, Aly-Khan A., Xie, Wanling, Steinharter, John A., E. Bakouny, Ziad, Martini, Dylan J., Fleischer, Justin H., Abou-Alaiwi, Sarah, Nassar, Amin, Nuzzo, Pier V., Kaymakcalan, Marina D., Braun, David A., Wei, Xiao X., Harshman, Lauren C., Bilen, Mehmet A., Choueiri, Toni K.

“…Cabozantinib is approved for the first and subsequent line treatment of metastatic clear-cell renal cell carcinoma (ccRCC) based on trials in which most…”
Get full text

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma by Nassar, Amin H., Mouw, Kent W., Jegede, Opeyemi, Shinagare, Atul B., Kim, Jaegil, Liu, Chia-Jen, Pomerantz, Mark, Harshman, Lauren C., Van Allen, Eliezer M., Wei, Xiao X., McGregor, Bradley, Choudhury, Atish D., Preston, Mark A., Dong, Fei, Signoretti, Sabina, Lindeman, Neal I., Bellmunt, Joaquim, Choueiri, Toni K., Sonpavde, Guru, Kwiatkowski, David J.

“…Background In metastatic urothelial carcinoma (mUC), predictive biomarkers that correlate with response to immune checkpoint inhibitors (ICIs) are lacking…”
Get full text

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel by Harshman, Lauren C, Chen, Yu-Hui, Liu, Glenn, Carducci, Michael A, Jarrard, David, Dreicer, Robert, Hahn, Noah, Garcia, Jorge A, Hussain, Maha, Shevrin, Daniel, Eisenberger, Mario, Kohli, Manish, Plimack, Elizabeth R, Cooney, Matthew, Vogelzang, Nicholas J, Picus, Joel, Dipaola, Robert, Sweeney, Christopher J

“…Purpose We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the context of a prospectively randomized clinical trial…”
Get full text

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study by Petrylak, Daniel P, Loriot, Yohann, Shaffer, David R, Braiteh, Fadi, Powderly, John, Harshman, Lauren C, Conkling, Paul, Delord, Jean-Pierre, Gordon, Michael, Kim, Joseph W, Sarkar, Indrani, Yuen, Kobe, Kadel, 3rd, Edward E, Mariathasan, Sanjeev, O'Hear, Carol, Narayanan, Sujata, Fassò, Marcella, Carroll, Susheela, Powles, Thomas

“…Atezolizumab [anti-programmed death-ligand 1 (anti-PD-L1)] is well tolerated and efficacious in multiple cancers, but has not been previously evaluated in…”
Get full text

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma by Lalani, Aly-Khan A, Xie, Wanling, Martini, Dylan J, Steinharter, John A, Norton, Craig K, Krajewski, Katherine M, Duquette, Audrey, Bossé, Dominick, Bellmunt, Joaquim, Van Allen, Eliezer M, McGregor, Bradley A, Creighton, Chad J, Harshman, Lauren C, Choueiri, Toni K

“…An elevated Neutrophil-to-lymphocyte ratio (NLR) is associated with worse outcomes in several malignancies. However, its role with contemporary immune…”
Get full text

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study by Martínez Chanzá, Nieves, Xie, Wanling, Asim Bilen, Mehmet, Dzimitrowicz, Hannah, Burkart, Jarred, Geynisman, Daniel M, Balakrishnan, Archana, Bowman, I Alex, Jain, Rohit, Stadler, Walter, Zakharia, Yousef, Narayan, Vivek, Beuselinck, Benoit, McKay, Rana R, Tripathi, Abhishek, Pachynski, Russell, Hahn, Andrew W, Hsu, JoAnn, Shah, Sumit A, Lam, Elaine T, Rose, Tracy L, Mega, Anthony E, Vogelzang, Nicholas, Harrison, Michael R, Mortazavi, Amir, Plimack, Elizabeth R, Vaishampayan, Ulka, Hammers, Hans, George, Saby, Haas, Naomi, Agarwal, Neeraj, Pal, Sumanta K, Srinivas, Sandy, Carneiro, Benedito A, Heng, Daniel Y C, Bosse, Dominick, Choueiri, Toni K, Harshman, Lauren C

“…Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib…”
Get full text

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone by McKay, Rana R, Ye, Huihui, Xie, Wanling, Lis, Rosina, Calagua, Carla, Zhang, Zhenwei, Trinh, Quoc-Dien, Chang, Steven L, Harshman, Lauren C, Ross, Ashley E, Pienta, Kenneth J, Lin, Daniel W, Ellis, William J, Montgomery, Bruce, Chang, Peter, Wagner, Andrew A, Bubley, Glenn J, Kibel, Adam S, Taplin, Mary-Ellen

“…Patients with locally advanced prostate cancer have an increased risk of cancer recurrence and mortality. In this phase II trial, we evaluate neoadjuvant…”
Get full text

Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the National Health and Nutrition Examination Survey by CHANG, Steven L, HARSHMAN, Lauren C, PRESTI, Joseph C

“…Previous studies suggest that some common medications alter prostate-specific antigen (PSA) levels. It remains unclear whether these reported medication…”
Get full text

Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805) by Harshman, Lauren C., Wang, Victoria X., Hamid, Anis A., Santone, Gabriella, Drake, Charles G., Carducci, Michael A., DiPaola, Robert S., Fichorova, Raina N., Sweeney, Christopher J.

“…Background The immunosuppressive cytokine interleukin‐ 8 (IL‐8), produced by tumor cells and some myeloid cells, promotes inflammation, angiogenesis, and…”
Get full text